Ovid and Takeda's epilepsy drug gets new life at Perceptive-backed NewCo
About 26 months after failing two Phase 3 trials, an epilepsy treatment candidate is getting plucked off biopharma's shelves and will be given a new chance at life. Life sciences investment firm Perceptive Advisors is ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.